Are research peptides legal in the United States?

The short answer, and why it cannot be shorter

Two things are true at once, and most coverage picks one. Most research peptides are not listed as federally scheduled controlled substances, so possessing one is not the kind of offence that possessing a Schedule II drug is. And no research peptide is FDA-approved for human use — which means that once a product is intended for human use, it is an unapproved new drug under the Federal Food, Drug, and Cosmetic Act, and distributing it violates the Act. The gap between those two facts is the entire subject.

That is a regulatory grey area, not a settled permission. It is also moving: several federal actions in 2026 have changed what is proposed, and none of them has yet changed what is final.

Three lanes, not one rulebook

The single most common error is treating “peptide regulation” as one thing. It runs through three separate channels, each with its own statutory test, its own list of substances, and its own timeline. A rule that moves in one lane frequently says nothing at all about the others.

• 503A — a state-licensed pharmacy compounding a drug for one identified patient against a prescription.
• 503B — an FDA-registered outsourcing facility compounding in bulk, generally without a patient-specific prescription.
• Research-use-only — material sold labelled for laboratory use, outside both compounding regimes entirely.

This framework, and which 2026 action lands in which lane, is set out in full in the three-lanes explainer.

Category 1 and Category 2 — what placement actually restricts

For the compounding lanes, the FDA sorts nominated bulk drug substances into categories. FDA titles them plainly: Category 1 is “Bulk Drug Substances Under Evaluation,” Category 2 “those that Raise Significant Safety Concerns,” Category 3 “nominated without adequate support.” Category 1 is an interim status carrying enforcement discretion during assessment — not authorisation, and not placement on the 503A Bulks List, which takes a final rule. In April 2026 the FDA removed twelve peptides from Category 2 after their nominations were withdrawn (docket FDA-2025-N-6895).

The precision that matters: removal from Category 2 is not authorisation to compound, and it does not move a substance into Category 1. FDA’s Category 1 list as updated May 14, 2026 contains none of the seven peptides the advisory committee reviewed — its only peptide-family entries are GHK-Cu (except injectable routes) and Vasoactive Intestinal Peptide. A vendor presenting the Category 2 removals as “peptides are being legalised” is describing something that did not happen.

What moved in 2026 — and what “proposed” means

On April 30, 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, having found no clinical need. The notice published in the Federal Register on May 1 and the comment window, extended to July 30, 2026, has closed. The agency is weighing comments. No final rule has issued — proposed and banned remain different words.

Separately, the FDA’s Pharmacy Compounding Advisory Committee met on July 23–24, 2026 and recommended six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax — for the 503A Bulks List, rejecting DSIP. Those votes are non-binding recommendations. Placement requires the FDA to act through rulemaking with HHS sign-off, a process observers expect to run into 2027. Nothing became compoundable on the day of the vote.

The recorded tallies and what the vote does and does not do are covered in the PCAC vote recap.

A “research use only” label is not a legal shield

This is the part most often misunderstood, and it is settled enough to state plainly: the disclaimer does not control the analysis. Intended use does. The FDA has issued a run of warning letters to peptide sellers — among them Summit Research Peptides (December 2024), USApeptide.com (February 2025), Pinnacle Peptides (December 2025) and Wholesale Peptide (June 2026) — each finding that despite labelling reading “research use only” or “not for human consumption,” evidence from the labelling and websites established the products were intended as drugs for human use. On that finding the products are unapproved new drugs under section 505(a).

The same theory drives private litigation. On August 12, 2026 Eli Lilly filed six federal lawsuits over retatrutide sales, pleading state unfair-competition and consumer-protection statutes rather than patent or FDCA claims, and arguing that the marketing conduct around a label — dosing charts, injection instructions, weight-loss claims, consumer-facing distribution — is evidence of intended human use. Those cases are unresolved: a lawsuit is an allegation, and no court has found any defendant liable.

The pleading architecture, and why Lilly avoided patent and FDCA claims, is examined in the retatrutide lawsuits piece.

States are moving too — and what a state law cannot do

Louisiana Act 374 took effect on August 1, 2026, the first state statute we can identify that legislates on peptides by name. Its enacted text restrains state licensing boards from prohibiting providers and pharmacists from working with peptides, conditioned on compliance with the federal compounding provisions and the applicable USP-NF chapters.

A state controls licensure; it does not control what federal law permits to be compounded. A statute telling state boards not to punish a pharmacist removes one enforcer, not the federal prohibition. Act 374 is drafted to avoid that collision — its protection only ever attaches to conduct that is already federally compliant.

What the legislature removed from the bill before passage, and why it matters, is in the Act 374 analysis.

What this does not mean

• This is not legal advice. It reports the regulatory position; it does not tell anyone what they may lawfully do.
• None of the 2026 movement is final. A proposal is not a rule, and an advisory recommendation is not an approval.
• “Not a controlled substance” is not the same as “approved,” and it is not a green light for human use.
• The position is evolving, and the dates on this page are part of its meaning.

How Prof. Peptide sources and checks what it publishes is set out in the methodology.